This post was originally published on this site

Shares of Sage Therapeutics soared more than 60 percent in premarket trading on Thursday after the company announced positive results in the testing a major depressive disorder (MDD) treatment.

Sage said in a release that 64 percent of patients achieved MDD remission using the SAGE-217 drug in the 15th day of treatment.

This is the second successful drug trial result in as many months for Sage. On Nov. 9, the company said brexanolone — a drug aimed at treating moderate and severe postpartum depression — met its main goal in two late-stage studies. The stock shot up 54.2 percent that day and is up 44.1 percent over the past month.

“These very encouraging data suggest the potential of SAGE-217 in the treatment of MDD as well as other mood-related disorders that we may pursue,” CEO Jeff Jonas said in a statement. “The positive activity and safety findings of SAGE-217 in MDD support advancing the program into later stage clinical development.”